Cite
HARVARD Citation
Franklin, M. et al. (2018). Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US. Current medical research and opinion. pp. 353-360. [Online].